Optimizing Management of Patients with Adult T Cell Leukemia-Lymphoma

Cancers

Jean A. Yared¹  Amy S. Kimball¹ 

关键词: adult T cell leukemia-lymphoma;    ATL;    ATLL;    allogeneic;    HTLV-1;    transplantation;    chemotherapy;    antiviral treatment;   

DOI  :  10.3390/cancers7040893

来源: mdpi

【 摘 要 】

Adult T cell leukemia-lymphoma is a rare disease with a high mortality rate, and is challenging for the clinician. Early allogeneic stem cell transplant can confer durable remission. As novel therapeutic agents become available to treat T cell malignancies, it is increasingly important that medical oncologists, hematologists, and hematopathologists recognize and accurately diagnose adult T cell leukemia-lymphoma. There is no uniform standard of treatment of adult T cell leukemia-lymphoma, and clinical trials remain critical to improving outcomes. Here we present one management approach based on the recent advances in treatment for adult T cell leukemia-lymphoma patients.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.